Patients with high TIL levels not only show better treatment response as evidenced by Ki67 reduction but also exhibit initially higher proliferative activity, which could indicate a more aggressive tumor phenotype responsive to immune-mediated interventions. This evidence concerns the gene MKI67 and neoplasm.